AMGN vs GILD: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
AMGN (Amgen) and GILD (Gilead Sciences) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
AMGN vs GILD: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AMGN | GILD | What it tells you |
|---|---|---|---|
| Market cap | $233.82B | $193.67B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 17.65 | 15.71 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.41 | 0.33 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 91% of range | 91% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 20.00 | 16.39 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AMGN and GILD affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMGN and GILD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMGN and GILD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Amgen (AMGN) do?
Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.
What does Gilead Sciences (GILD) do?
Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. Its HIV franchise, anchored by widely used single-tablet regimens like Biktarvy and the twice-yearly prevention injection Yeztugo (lenacapavir) for pre-exposure prophylaxis, generates the bulk of its revenue and is a global standard of care: HIV sales were about $5.7 billion in the second quarter of 2026, up 12% from a year earlier. Gilead also has a significant presence in liver diseases, including hepatitis B and C, where its cures transformed treatment, and in COVID-19 with the antiviral remdesivir (Veklury), now a shrinking contributor. Gilead has expanded into oncology through acquisitions, building a portfolio in cell therapy (CAR-T) and antibody-drug conjugates for cancers such as breast and bladder cancer, and in 2026 it added Arcellx, Tubulis and Ouro Medicines, plus an October 2026 partnership with Vir Biotechnology on T-cell engagers for solid tumors. The company makes money by selling these prescription medicines worldwide, supported by patents and strong pricing. Headquartered in Foster City, California, Gilead generated about $30.5 billion of revenue over the last twelve months, pays a dividend of $3.28 per share a year, and is investing to diversify into oncology and other areas as it manages future patent expirations.
AMGN vs GILD: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AMGN drivers: Rare disease and Horizon assets; Obesity and metabolic pipeline.
- GILD drivers: Dominant HIV franchise; Oncology expansion, now accelerated by deals.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. For GILD, gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk.
AMGN or GILD: which should you pick?
AMGN vs GILD: the full fundamentals
AMGN. As of October 16, 2026, Amgen trades at about 27x trailing GAAP earnings and about 18x forward earnings, with EV/EBITDA near 16x, a rerating from early 2026 after the shares gained about a third. The dividend yield has fallen to about 2.3% as the price rose. Consensus for the Q3 2026 report on November 3 is adjusted EPS of ~$5.76 on ~$10.06 billion of revenue; the 29 analysts covering the stock have an average target of about $395, below the current price.
GILD. Gilead is valued as a mature, cash-generative biopharma at about 16 times forward earnings, above where it traded a year ago after a roughly 28% gain in 2026. Reported earnings are negative over the last twelve months because of about $11 billion of acquired research charges, so investors focus on product revenue (guided to $30.1-30.4 billion for 2026) and free cash flow. Third-quarter results are due October 29, 2026, with consensus near $2.20 of adjusted EPS on about $7.8 billion of revenue.
Headline figures (approximate, October 2026): AMGN shows revenue (ttm) ~$38.1 billion, revenue growth (q2 2026, yoy) ~9.5%, operating margin ~36%, net income (ttm) ~$8.7 billion; GILD shows revenue (ttm) ~$30.5 billion, revenue growth (latest quarter, yoy) ~10%, operating margin ~34%, net income (ttm) ~-$3.2 billion (acquired IPR&D charges).
The bottom line: AMGN vs GILD
AMGN and GILD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMGN and GILD exposure against your real portfolio. It is not an investment adviser.
Wondering how AMGN or GILD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Amgen with AI
Connect the broker you already use and ask Walnut's AI how AMGN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between AMGN and GILD?
+
Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AMGN or GILD the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AMGN or GILD?
+
On forward P/E (as of October 2026), AMGN trades at 17.65x and GILD at 15.71x, so GILD is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AMGN and GILD?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AMGN vs GILD?
+
AMGN: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including its obesity programs, can fail in late-stage trials or face regulatory setbacks. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition left Amgen with about ~$57 billion of total debt against ~$14 billion of cash as of mid-2026. After a 33% year-to-date gain, the share price of $436 sits above the ~$395 average analyst target, and consensus expects only about 5% EPS growth in 2026 and 6% in 2027, so the valuation now assumes more than the near-term numbers show. Litigation, manufacturing, and safety risks are inherent to the industry. GILD: Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. Hepatitis C revenue declined sharply after its cures shrank the patient pool, illustrating how success can erode markets, and Veklury sales are fading (2026 guidance cut to about $300 million). Its oncology expansion has been costly and uneven: the 2026 acquisitions pushed reported results to a GAAP loss of about $10.5 billion in the second quarter and a trailing net loss of about $3.2 billion, and the Immunomedics impairment shows acquired programs can underperform. Debt stood near $26 billion against about $4.9 billion of cash at the end of June. Drug development is risky, with frequent trial failures. The company faces regulatory, reimbursement, and drug-pricing policy pressures, including in the US. After a strong 2026 run the stock trades near the average analyst target of about $160, leaving less room for disappointment. Diversifying away from virology successfully is essential but unproven at scale.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMGN or GILD; figures are approximate and dated (as of October 2026). Verify current data before investing.